#FutureFresenius: REJUVENATE in Action – Delivering accelerated performance for long-term value creation
FY/25: Strong organic revenue and excellent Core EPS growth
- Organic revenue growth of 7%1,2, reflecting the consistent execution across Fresenius Kabi and Fresenius Helios
- Group EBIT1 up 6%3 in constant currency, driven in particular by Fresenius Kabi’s Growth Vectors and the strong performance of Fresenius Helios in Spain
- Core EPS1,4 increased 12%3 in constant currency based on strong operating results and significantly decreased interest expense
- Structural EBIT margin ambition increased for Fresenius Kabi to 17 to 19% (previously 16 to 18%)
- Constant currency Core EPS growth1,4 established as new guidance metric is expected to be in the range of 5 to 10%3 in FY/26; organic revenue growth2 projected to be in the range of 4 to 7% in FY/26.
- Dividend proposal of €1.05 per share; year-on-year increase of 5%, in line with the Company's dividend payout ratio of 30 to 40%.
1 Before special items; 2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation; 3 Growth rate adjusted for Argentina hyperinflation; 4 Excluding Fresenius Medical Care
View the full FY/25 update in the Financial Results section.
Read more about our company strategy!
May 06, 2026 - 01:30 pm
Bad Homburg, Germany
Conference Call Q1 2026
-
Annual Report 2025
The Fresenius Annual Report 2025 is available as an online-version with enhanced functionality and as a PDF.
Over the past three years, we have successfully implemented our #FutureFresenius strategy and created a new Fresenius that is innovative, relevant, resilient, and adaptable. Highlights include a message from CEO Michael Sen, success stories from Fresenius Kabi and Fresenius Helios, our first ESRS-compliant sustainability statement, and financial performance insights.
-
Sustainability Statement 2025
Sustainability is a part of Fresenius’ corporate strategy. Our Sustainability Statement shows how we address environmental, social, and governance topics and manage the associated impacts, risks, and opportunities.
"2025 was a pivotal year for Fresenius. With disciplined execution of our #FutureFresenius strategy and a strong performance from Team Fresenius, we met our upgraded full-year guidance by delivering another quarter of competitive growth [...]. 2025 capped a year of continued momentum across the Company: We further strengthened the balance sheet, and upgraded our guidance, while preparing the business through targeted investment for the next phase of growth. All of this leads to a proposed dividend of €1.05 per share, underscoring our commitment to creating shareholder value [...]. With #FutureFresenius we have transformed our Company, positioning ourselves to deliver future success in a new world order. Looking ahead, we enter 2026 with strong foundations and clear priorities [...]."
Michael Sen, Chairman of the Management Board
Financial Results
FY 2025: REJUVENATE in Action – Delivering accelerated performance for long-term value creation!
Outlook
New guidance metric established: Fresenius Outlook 2026 at a glance.
Financial Reports
Discover Fresenius financial reports and presentations here!
Goals & Strategy
#FutureFresenius is clearly paying-off. Find out more about our company's strategy!
Investor Feedback
Open dialogue is valuable for us.
You can submit your feedback quickly and easily using the link below (anonymously if you prefer).
You will be redirected to QuantiFire which conducts this survey in own controllership.
News
-
Fresenius expands European production capacity to enhance healthcare supply chain resilience
![]()
Fresenius expands European production capacity to enhance healthcare supply chain resilience
Fresenius is strengthening its European manufacturing network with new and expanded production capabilities for intravenous (IV) fluids in Poland and Italy. This week, the company opened a new IV fluids production line in Kutno, Poland, and expanded its manufacturing and warehouse infrastructure in Isola della Scala, Italy.
September 25, 2026 · Fresenius Kabi
-
Fresenius expands Medical Nutrition Portfolio with new real-food-based enteral nutrition concept
![]()
Fresenius expands Medical Nutrition Portfolio with new real-food-based enteral nutrition concept
NutriChef launches in several European markets and combines real food ingredients1 with the consistency and nutritional completeness of medical nutritionThe launch of NutriChef, the fifth product launch within Fresenius’ Medical Nutrition portfolio in 2026, reflects the company’s commitment to patient-centered innovation-led growth and further strengthens its portfolio in nutritional careNutriChef expands Fresenius’ enteral nutrition offering with a real-food-based concept designed around the needs of patients, caregivers, and healthcare professionalsMedical Nutrition is an attractive healthcare market supported by aging populations, increased demand for homecare, and growing awareness of the role of nutrition in patient careFresenius announced today the launch of NutriChef, a new enteral nutrition option that combines real food ingredients1 such as fruit and vegetables while maintaining the nutritional completeness required for medical nutrition, in Germany, Switzerland, Norway, Netherlands, Denmark, and Sweden.The product is designed to bridge the gap between conventional formula-based tube feeding and the familiarity associated with real meals and home-prepared foods. Available in three nutritionally complete, meal-inspired varieties2, they contain ingredients derived from 21 different plants and more than 75 percent real food ingredients, including water and oils1. The product provides high energy and protein as well as a blend of soluble and insoluble fibers.“For many patients, the challenge is not only getting the nutrition they need. It is adapting to a new reality,” said Sebastien Guery, Executive Vice President Business Unit Medical Nutrition. “NutriChef responds to that need by combining familiar foods into enteral feeding with the safety, consistency and nutritional standards required in medical care. It is also a testament to the innovation-led growth of Fresenius, reflecting our ability to translate evolving patient needs into differentiated innovations and meaningful portfolio expansion.”Developed for patients who require enteral nutrition, the new offering combines familiar food-based ingredients with the reliability and quality standards expected from medical nutrition. It offers patients, caregivers, and healthcare professionals an additional option that brings familiar food concepts into nutritional care.As populations age and more care shifts beyond the hospital into outpatient and homecare settings, nutritional support is becoming increasingly important across healthcare systems. Fresenius continues to see strong long-term demand in Medical Nutrition, supported by demographic trends, growing awareness of disease-related malnutrition, and the need for solutions that fit into patients’ daily lives.As the fifth addition to Fresenius’ Medical Nutrition portfolio introduced in 2026, NutriChef underscores the company’s continued investment in nutritional care across enteral and parenteral nutrition, the company continues to expand access to high-quality medical nutrition while addressing practical challenges faced by patients, caregivers, and healthcare professionals. As part of #FutureFresenius, the company continues to strengthen its portfolio with differentiated solutions that address evolving patient needs.NutriChef is a food for special medical purposes for the dietary management of disease-related malnutrition, to be used under medical supervision. Product availability may vary by market.NutriChef is essentially designed as an adult medical nutrition product, with limited, controlled use in:children >3 years (restricted)adolescents (possible full use only with medical supervision)References1 Fresenius Kabi. NutriChef Ingredient List and Product Specification. Fresenius Kabi; 2026.2 Fresenius Kabi Market Research; Real Food & Tube Feeding Insights Study, 2022.
September 07, 2026 · Fresenius Kabi
-
Brief News
Q2 2026 Aide Memoire available
Fresenius announced today that the Company's Q2 2026 Aide Memoire is now available on the Company's financial results section.As a service to capital market participants, Fresenius provides a quarterly Aide Memoire ahead of the publication of the Company's quarterly results. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. Fresenius' Q2 2026 financial results will be published on August 5, 2026.
July 15, 2026 · Fresenius
-
Brief News
GKV Stabilization Act approved
The German Bundestag and Bundesrat approved the Act to Stabilize Contributions Rates in the Statutory Health Insurance System (GKV-Beitragssatzstabilisierungsgesetz) on July 10, 2026.
July 13, 2026 · Fresenius
-
Brief News
AI assistant enhances access to Investor Relations information
Today, Fresenius has launched the AI-powered assistant – “AskFRE” – on its Investor Relations (IR) website, marking an important step in advancing its digital capital markets communications. The solution is a joint initiative of the Fresenius AI Center of Excellence and the Investor Relations team.With AskFRE, visitors can now interact with an integrated AI chatbot that provides direct answers to capital market-relevant information. This includes financial results, company updates and other IR content – based exclusively on publicly available Fresenius disclosures.In an increasingly fast-paced and data-driven environment, digital investor relations play a key role in delivering timely, transparent and stakeholder-focused communication. AskFRE supports this ambition by enabling more intuitive access to financial information and tailored user interactions, while reinforcing the consistency and accessibility of Fresenius’ disclosures.With AskFRE, Fresenius underscores its commitment to advancing a best in class digital investor relations experience.AskFRE is now available: https://www.fresenius.com/AskFRE-Your-IR-Assistant
May 26, 2026 · Fresenius
Stay Connected with Fresenius Investor Relations on LinkedIn
Follow Fresenius Investor Relations for expert insights and latest news that contribute to the Fresenius equity story, and exclusive content from our team. Join our growing community and be part of the conversation!
mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.
The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies.
Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor.
This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius.
Fresenius in Spain
The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.
mAbxience, a Fresenius entity, has entered into a collaboration with HP Inc. to develop an artificial intelligence (AI) solution aimed at making biomanufacturing more efficient and reliable.
The joint project uses AI and digital-twin technology to model and optimize key steps in the production of monoclonal antibodies and biosimilars. By simulating critical cell-culture parameters and predicting process outcomes, the system is designed to support more consistent yields, faster development cycles, and better control of large-scale manufacturing environments. This is a showcase of Fresenius’ pathway in leveraging AI and digital solutions, from production and supply-chain to care delivery, improving treatment quality, and expanding access to state-of-the-art therapies.
Both partners view the technology as a significant step toward more data-driven and tightly managed bioproduction. The prototype, developed with real manufacturing data and validated in an industrial setting, enables teams to test scenarios virtually before applying them on the shop floor.
This initiative is the first project under a broader strategic framework between HP and mAbxience at its manufacturing facility in Leon, Spain, and has the potential to be rolled out across additional sites. It represents another milestone in advancing Fresenius’ (Bio)Pharma platform and supports the goals of #FutureFresenius.
Fresenius in Spain
The global healthcare company Fresenius is deeply rooted in Spain. With Quirónsalud, the country’s leading hospital operator, and Fresenius Kabi, offering essential medicines and technologies for critically and chronically ill patients, the company makes a decisive difference in the life-quality of Spanish citizens. With the majority acquisition of mAbxience in 2022, Fresenius created a dedicated and vertically integrated biosimilars development and manufacturing platform. In line with its #FutureFresenius strategy, the company is further scaling in (Bio)Pharma to deliver simplification and drive efficiencies, underscoring its commitment to offering accessible, innovative, and high-quality healthcare solutions.
Members of the Management Board of Fresenius Management SE (General Partner):
Michael Sen became CEO (Chairman of the Management Board) of Fresenius on October 1, 2022. He joined Fresenius in April 2021 as CEO of Fresenius Kabi. Before joining Fresenius Kabi, Michael Sen was a member of the Management Board of Siemens AG, where he was responsible for the healthcare business Siemens Healthineers and for Siemens’ energy business. Prior to that, he was Chief Financial Officer of E.ON SE. At the start of his professional career, Michael Sen completed an apprenticeship at Siemens in Berlin and then studied business administration at the Technical University of Berlin.
Pierluigi Antonelli joined the Management Board of Fresenius in March 2023 with responsibility for Fresenius Kabi. In his previous role since 2019, he was the CEO of Angelini Pharma, a company of the Italian Angelini Group specializing in brain health and consumer health. Prior to that, he held senior leadership positions at Novartis Oncology, Sandoz, Merck & Co. and Bristol Myers Squibb in the United States and across Europe.
Sara Hennicken was appointed CFO of Fresenius as of September 1, 2022. She joined the Group in 2019 as Senior Vice President Global Treasury & Corporate Finance for Fresenius and Fresenius Medical Care. Previously, she spent 14 years in investment banking, including nine years at Deutsche Bank, lastly as Managing Director and Senior Client Executive in Corporate Finance Coverage before moving to Fresenius. Between 2005 and 2010 she worked for Citigroup in Frankfurt and London. Sara Hennicken studied economics in Germany and in the United States.
Dr. Christian Pawlu joined the Management Board of Fresenius in July 2026 with responsibility for Fresenius Helios. He joined Fresenius in 2021, initially serving as Head of Corporate Development at Fresenius Kabi, among other roles, and then, starting in 2022, as Head of Corporate Development at Fresenius. Starting in 2025, Christian Pawlu served Chief Operating Officer of Fresenius Helios. Prior to joining Fresenius, Christian Pawlu was a member of the Executive Committee at Sandoz, CEO of a high-tech startup, and a Partner at McKinsey & Company. Christian Pawlu studied medicine in Munich and Freiburg and also earned his doctorate in Freiburg.
Michael Moser joined the Management Board of Fresenius in July 2023. He is responsible for Legal, Compliance, Risk Management, Sustainability, Human Resources, Corporate Audit and transformation of the Vamed businesses. After starting his career at Baker McKenzie, he joined E.ON SE in 2008. During this time, he inter alia became member of the Management Board of the stock listed company ENEVA in Brazil, steered the listing of Uniper and served as Deputy CEO and CFO of Enerjisa, the stock listed leading energy company in Turkey. He has received university degrees in law and business economics in Germany, USA, UK, Switzerland and China.
Contact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
board@fresenius.com
The Fresenius Management Board oversees the Human Rights Program. Group-wide governance structures and clearly defined responsibilities support its implementation.
The Group Human Rights Office is located within Group Sustainability and reports to the Head of Group Sustainability, who reports directly to the Fresenius Management Board. The Human Rights Office is responsible for the overall human rights due diligence approach, including the development and management of the human rights risk assessment methodology, support for Operating Companies in implementing relevant processes, and monitoring of their activities.
Each Operating Company has appointed a Human Rights Function that is responsible for implementing the Human Rights Program in its respective business. The function reports to the Group Human Rights Office and to the Operating Company's Board or Management Team.
In addition, each Operating Company designates subject matter experts in relevant departments, including Human Resources, Procurement, and Occupational Health and Safety. They contribute their expertise to risk analyses and support the implementation of preventive and mitigating activities.
To facilitate exchange on human rights due diligence and related activities across the Group, we have established a Human Rights Council. It serves as a Group-wide platform and brings together representatives from the Group Human Rights Office, the Human Rights Functions, and relevant expert functions. External experts may be invited as needed to provide specialized insights and enrich discussions on specific human rights topics.
Human Rights Insights
Explore our interviews:
-
Respecting Human Rights Globally
Fresenius Kabi is committed to respecting human rights across its global supply chains. Marco Kraemer, Director Supplier Quality Management & Human Rights Function, explains how business partners are engaged through binding standards and how industry initiatives for audit-sharing and best practices are leveraged – enhancing transparency, efficiency, and sustainable responsibility.
-
Leveraging Synergies Effectively
Helios Germany firmly embeds human rights into daily hospital operations. Tim Schleifenecker, Head of Corporate Governance, explains how binding policies, training, and the internal control system ensure employees and partners comply with human rights standards. These synergies enhance transparency, risk management, and a culture of responsibility.
-
Human Rights in Hospital Value Chains
Fresenius Helios embeds human rights across its hospital supply chain. Imke Wagenknecht, Sustainability Manager for Procurement and Logistics, shows how procurement enforces a binding supplier Code of Conduct, and uses risk-based analyses to tackle potential risks – building transparency, trust, and long-term resilience.
-
Managing Risks in Own Operations
Fresenius strengthens human rights across its business areas. Sabine Schmitt and Lisa Armbruster explain how potential risks such as workplace safety or discrimination are identified through regular analyses and addressed via targeted prevention.
Human Rights at Fresenius
Our Human Rights ProgramContact
Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
humanrights@fresenius.com
Human Rights Program
Our Human Rights Program Risk Assessment & Impacts Prevention & Remediation Systems and Procedures for Reporting MisconductWhistleblowing system
Reports on possible human rights or other types of compliance violations can be reported around the clock, either anonymously or by name, via our whistleblower system*:
Phone number: +49 (0) 800 181 1338*
https://freseniusgroup.ethicspoint.com
More infos about our grievance mechanism
*The prices of your mobile or landline contract apply
The reporting on the respect for human rights for the year 2024 and following can be found in our Sustainability Report (CSRD Report). Further information on Fresenius' human rights program is available here: fresenius.com/en/human-rights
Fresenius announced today the launch of its denosumab biosimilars, Conexxence®1 (denosumab) and Bomyntra®2 (denosumab), in Europe.
These biosimilars received approval from the European Commission in July 2025 for all indications of the reference products Prolia®3 (denosumab) and Xgeva®4 (denosumab), respectively.
“Being the first biosimilar company with a pre-filled syringe for the denosumab oncology indication in Europe, showcases our commitment to offering new treatment options that support patient care and affordability across Europe,” said Dr. Sang Jin Pak, President Biopharma.
This milestone marks the next step in the company’s ambition to drive accessibility to high-quality biosimilar therapies, with multiple molecules in early and late-stage development. By continuing its successful track record in the biosimilars space, Fresenius further strengthens its (Bio)Pharma platform, a key pillar of the #FutureFresenius strategy.
1. Conexxence® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
2. Bomyntra® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
3. Prolia® is a registered trademarks of Amgen Inc.
4. Xgeva® is a registered trademarks of Amgen Inc.
Fresenius announced today the launch of its denosumab biosimilars, Conexxence®1 (denosumab) and Bomyntra®2 (denosumab), in Europe.
These biosimilars received approval from the European Commission in July 2025 for all indications of the reference products Prolia®3 (denosumab) and Xgeva®4 (denosumab), respectively.
“Being the first biosimilar company with a pre-filled syringe for the denosumab oncology indication in Europe, showcases our commitment to offering new treatment options that support patient care and affordability across Europe,” said Dr. Sang Jin Pak, President Biopharma.
This milestone marks the next step in the company’s ambition to drive accessibility to high-quality biosimilar therapies, with multiple molecules in early and late-stage development. By continuing its successful track record in the biosimilars space, Fresenius further strengthens its (Bio)Pharma platform, a key pillar of the #FutureFresenius strategy.
1. Conexxence® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
2. Bomyntra® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries.
3. Prolia® is a registered trademarks of Amgen Inc.
4. Xgeva® is a registered trademarks of Amgen Inc.
Worldwide
Partnership with Städel Museum to continue
Fresenius and the Städel Museum have been working together since 2024 to make art accessible to a wider audience and demonstrate their commitment to the region. They are now extending their partnership for a further two years.
Worldwide
Lung cancer screening: A game changer
For a long time, lung cancer was only discovered when it was almost too late for those affected. A new lung cancer screening program is now helping to change the situation – giving millions of people a real chance of early diagnosis and treatment.
Germany
“We combine various innovative solutions to achieve better patient outcomes step by step.”
Helios Hospital Berlin-Buch is one of the first hospitals in Germany to use augmented reality in the operating room.
Germany
First meeting of the year for the Sustainability Advisory Board in Friedberg
Our Sustainability Advisory Board got together for the first meeting of this year at Fresenius Kabi’s production and logistics site in Friedberg.
Worldwide
How Fresenius employees help people with cancer in every phase of the disease
They serve patients beyond expectations and always give their best – not just in the fight against cancer, but also when striving for the highest possible quality of life.
Worldwide
More time for patients thanks to AI in the consulting room
With Scribe, our Quirónsalud hospitals are revolutionizing the Spanish healthcare system. The Ai-powered application enhances efficiency and quality while also strengthening the doctor–patient relationship – for more humanity in medicine.
Worldwide
Antimicrobial resistance is on the rise: How Fresenius responds across all businesses
Antimicrobial resistance (AMR) is a growing global threat. Fresenius is stepping up, through responsible manufacturing, hospital hygiene, and targeted antibiotic use, to help ensure these life-saving medicines remain effective.
Worldwide
On World Prematurity Day:
A little medical miracle at the Helios hospital in Pforzheim
Worldwide
Walking in a Patient’s Shoes
How Fresenius Kabi is using immersive simulations to deepen understanding of chronic illness.
Worldwide
Celebrating 50 Years of Fresubin
This year marks a major milestone in our company’s history: the 50th anniversary of Fresubin®. What began as a clinical solution in 1975 has grown into a trusted and comprehensive enteral nutrition product brand for patients around the world.
Worldwide
Earlier detection, more targeted treatment: Helios sets new standards in diagnosing lung cancer
Doctors are already setting new standards in the early diagnosis of disease with the robot-assisted “Ion endoluminal system” for bronchoscopy.
Deutschland
Committed to Life: Fresenius now fresher and more modern with new brand identity
#FutureFresenius is making the company fit for the future. And the brand identity must reflect and support this.
Worldwide
Comprehensive Care and Compassion: Fresenius' Commitment in Breast Cancer Treatment
Fresenius highlights its commitment to delivering excellent patient care and advancing medical innovation. One patient’s story shows how we bring hope and compassion when it matters most.
Worldwide
When Art Becomes Measurable
How Quirónsalud explores the impact of images on our well-being and the implications for new approaches in patient care
Worldwide
The people behind cancer care
On today’s World Cancer Day, Fresenius highlights what individualized cancer care means in practice. One patient’s story shows why seeing the whole person behind the diagnosis matters across the entire patient journey.
Worldwide
How Fresenius turns science into better patient care
Advances in medicine can save lives – but only when they reach patients. On today’s World Health Day, explore how Fresenius’ businesses bring research & development, new technology, and care together to help improve outcomes for patients.
Worldwide
Sustainability at Fresenius: Three questions for Mapi Henríquez de Armas, Director Sustainability at Quirónsalud
"While adapting to climate change is managed at a local level, we have set global emission reduction targets that help us to meet related expectations and to coordinate our efforts."
Worldwide
Sustainability at Fresenius: Five questions for Sarah Tix, Head of Group Sustainability
"In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies."
Germany
“The new ADC medicines represent a real revolution in treatment. This promising therapy can give many patients new hope.”
Professor Dr. Michael Untch from Helios Hospital Berlin-Buch explains how the new antibody-drug conjugates (ADCs) are changing the fight against cancer.
USA
“The flexibility of our Lovo and Cue cell processing systems was the key to success!”
Read our interview with Chris Wegener, to find out more about the device development for CAR-T cell therapy at Fresenius Kabi.
Germany
CAR-T cell therapy: Revolutionary chances of a cure, but costs still too high
How Fresenius Kabi is revolutionizing the treatment of cancer patients with the help of the Lovo and Cue cell processing systems.
Europe
Fresenius is a new partner of the Städel Museum
By supporting the renowned museum foundation, the healthcare company demonstrates its social responsibility. The partnership is at the same time a clear commitment to Frankfurt and the Rhine-Main region.
Germany
"Immunotherapies: Boosting Cures and more Patient Wellbeing"
Read our interview to find out what Dr. Anna Ossami Saidy, a doctor in training at the Helios Clinic Berlin-Buch, is currently researching.
Germany
Optimized colorectal cancer screening with AI
How artificial intelligence helps to detect polyps that can’t be seen by the human eye
Germany
CAR T cell therapy: Innovative therapy with the aid of genetically modified cells
“Personalized tumor medicine can be more effective at fighting tumors and produce beneficial therapies with fewer side effects.”
Germany
Welcome to our new podcast format: “Talk Time – CEO Insights with Michael Sen”!
Get to know more about how this year started for Michael Sen, his view on trends like AI in health care and health equity.
Germany
New year, good resolutions: Eating a vegan diet can do a lot for your health and the environment!
Hendrik Otto and Verena Kaiser from Helios explain the benefits of changing your diet
Europe
HOPE gives hope
Quirónsalud focuses on digitalisation to improve oncology patient care
Germany
"This is a tremendous win for the patients"
Interview with Prof. Iwasaki, winner of the Else Kröner Fresenius Prize for Medical Research 2023, endowed with 2.5 million euros.
Germany
Sustainably anesthetized
Anesthetic gas recycling reduces greenhouse gas emissions by 90 percent
Latin America
Planting trees and changing hearts
Fresenius Kabi Employees in the Dominican Republic are working to create a healthier environment.
Europe
‘Sometimes we understand each other without words’
Dr. Veronika Wolter is the first deaf person in Germany to achieve the position of chief physician. She herself uses a hearing prosthesis, and understands her patients very well.
Europe
A robot at the operating table
Fresenius Helios uses the latest robotic technology to make surgery gentler for patients – for example at Helios Hospital Erfurt in Germany.
Europe
Growing up with parenteral nutrition
How two brave adventurers from Switzerland are exploring the world step-by-step.
Europe
From a local pharmacy to a global corporation
As a leading global healthcare group we are dedicated to medicine and human health - values we have upheld since our founding as a pharmacy lab in 1912.